ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ADCT-602’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ADCT-602 is expected to reach an annual total of $44 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ADCT-602 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia. The therapeutic candidate is administered through intravenous route. It is an antibody drug conjugate composed of the humanized anti-human CD22 monoclonal antibody epratuzumab (hLL2) conjugated to pyrrolobenzodiazepine PBD dimer toxin. The drug candidate is developed based on pyrrolobenzodiazepine (PBD) technology. This technology enables cytotoxic agents to target antibodies using biodegradable linkers. It was also under development for non-Hodgkin lymphoma such as diffuse large B-cell lymphoma.
ADC Therapeutics Overview
ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.
The company reported revenues of (US Dollars) US$33.9 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$261.7 million in FY2021, compared to an operating loss of US$219.3 million in FY2020. The net loss of the company was US$230 million in FY2021, compared to a net loss of US$246.3 million in FY2020. The company reported revenues of US$76.3 million for the third quarter ended September 2022, compared to a revenue of US$17.3 million the previous quarter.
For a complete picture of ADCT-602’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.